Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Head and Neck Neoplasms 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Penile Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Melanoma 1Colonic Neoplasms 1Castration Resistant Prostate Cancer 1Carcinoma, Renal Cell 1Breast Neoplasms 1Anus Neoplasms 1

Interventions

Doxorubicin 20Cyclophosphamide 18Radiotherapy 17Ifosfamide 13Vincristine 12Magnetic Resonance Spectroscopy 12Specimen Handling 11Biopsy 10Etoposide 9Filgrastim 8Dactinomycin 8X-Rays 6Temozolomide 6Sirolimus 6Phantoms, Imaging 6Melphalan 6temsirolimus 5cixutumumab 5Thalidomide 5Celecoxib 5Sorafenib 4Radiation 4Nuclear Medicine Department, Hospital 4Ipilimumab 4Fluorodeoxyglucose F18 4Chemotherapy, Adjuvant 4Carboplatin 4pazopanib 3ixabepilone 3cabozantinib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Sarcoma × bintrafusp alfa protein, human × Clear all
NCT04648826 2021-12-17

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

National Institutes of Health Clinical Center (CC)

Phase 1/2 Withdrawn
DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡